Partial Cardiac Denervation for Preventing Atrial Fibrillation After CABG
NCT07918781, Not applicable, Not yet recruiting, China National Center for Cardiovascular Diseases
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Partial Cardiac Denervation for Preventing Atrial Fibrillation After CABG | ClinicalTrials.gov |
| NCT number | NCT07918781 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 1,470 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | China National Center for Cardiovascular Diseases | ClinicalTrials.gov |
| Conditions | Postoperative Atrial Fibrillation, Coronary Artery Disease | ClinicalTrials.gov |
| Interventions | Partial Cardiac Denervation | ClinicalTrials.gov |
| First posted | 2026-11-05 | ClinicalTrials.gov |
| Last updated | 2026-11-05 | ClinicalTrials.gov |
Registered outcomes 19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Incidence of Postoperative Atrial Fibrillation Within 6 Postoperative Days | From admission to the intensive care unit after surgery until postoperative day 6. | The proportion of participants with documented new-onset postoperative atrial fibrillation (POAF). POAF is defined as an episode of atrial fibrillation characterized by irregularly irregular RR intervals and the absence of discernible P waves, lasting more than 30 seconds. Continuous electrocardiographic recordings will be centrally reviewed by the blinded ECG Core Laboratory. | ClinicalTrials.gov |
| Primary | Time to First Occurrence of the Composite Clinical Outcome | From surgery until 3 years after enrollment of the last participant, with a minimum follow-up of 3 years for each participant. | Time from surgery to the first occurrence of any component of the composite outcome, including all-cause death, stroke, systemic embolism, myocardial infarction, readmission for cardiac reasons, or post-discharge atrial fibrillation. Suspected clinical events will be adjudicated by an independent Clinical Event Adjudication Committee blinded to treatment allocation. Post-discharge atrial fibrillation events will be reviewed by the blinded ECG Core Laboratory. | ClinicalTrials.gov |
| Secondary | Postoperative Length of Hospital Stay | From the date of surgery through discharge from the index hospitalization (an estimated period of up to 30 days) | The number of days from the date of surgery to hospital discharge. | ClinicalTrials.gov |
| Secondary | Total Hospitalization Costs | From the date of surgery through discharge from the index hospitalization (an estimated period of up to 30 days) | Total medical costs incurred during the index hospitalization. | ClinicalTrials.gov |
| Secondary | Incidence of Perioperative All-Cause Mortality | From the date of surgery through discharge from the index hospitalization (an estimated period of up to 30 days) | The proportion of participants who die from any cause during the perioperative hospitalization. | ClinicalTrials.gov |
| Secondary | Incidence of Perioperative New-Onset Stroke | From the date of surgery through discharge from the index hospitalization (an estimated period of up to 30 days) | The proportion of participants who experience a new-onset stroke during the perioperative hospitalization, as adjudicated by the blinded Clinical Event Adjudication Committee according to predefined endpoint criteria. | ClinicalTrials.gov |
| Secondary | Incidence of Perioperative Myocardial Infarction | From the date of surgery through discharge from the index hospitalization (an estimated period of up to 30 days) | The proportion of participants who experience myocardial infarction during the perioperative hospitalization, as adjudicated by the blinded Clinical Event Adjudication Committee according to predefined endpoint criteria. | ClinicalTrials.gov |
| Secondary | Postoperative Atrial Fibrillation Burden Within 6 Postoperative Days | From admission to the intensive care unit after surgery until postoperative day 6. | The proportion of analyzable electrocardiographic monitoring time spent in atrial fibrillation during the early postoperative monitoring period, as determined by the blinded ECG Core Laboratory. | ClinicalTrials.gov |
| Secondary | Number of Postoperative Atrial Fibrillation Episodes Within 6 Postoperative Days | From admission to the intensive care unit after surgery until postoperative day 6. | The total number of documented postoperative atrial fibrillation episodes per participant during the early postoperative monitoring period, as determined by the blinded ECG Core Laboratory. | ClinicalTrials.gov |
| Secondary | Duration of Postoperative Atrial Fibrillation Within 6 Postoperative Days | From admission to the intensive care unit after surgery until postoperative day 6. | The cumulative duration of documented postoperative atrial fibrillation episodes during the early postoperative monitoring period, as determined by the blinded ECG Core Laboratory. | ClinicalTrials.gov |
| Secondary | Incidence of Post-Discharge Atrial Fibrillation | From discharge until the end of study follow-up, with a minimum follow-up of 3 years for each participant. | The proportion of participants with atrial fibrillation documented after discharge by scheduled 3-day ambulatory electrocardiographic monitoring or by clinically obtained electrocardiographic recordings. All suspected events will be reviewed by the blinded ECG Core Laboratory. | ClinicalTrials.gov |
| Secondary | Post-Discharge Atrial Fibrillation Burden | At 3 months, 1 year, and annually thereafter until study completion, with a minimum follow-up of 3 years for each participant. | The proportion of analyzable ambulatory electrocardiographic monitoring time spent in atrial fibrillation during each scheduled 3-day monitoring period, as determined by the blinded ECG Core Laboratory. | ClinicalTrials.gov |
| Secondary | Incidence of Non-Atrial Fibrillation Arrhythmias | From surgery until the end of study follow-up, with a minimum follow-up of 3 years for each participant. | The proportion of participants with predefined non-atrial fibrillation arrhythmias, including third-degree atrioventricular block, frequent premature atrial contractions, and frequent premature ventricular contractions, as determined by the blinded ECG Core Laboratory. | ClinicalTrials.gov |
| Secondary | Heart Rate Variability Parameters | During the first 6 postoperative days and at 3 months, 1 year, and annually thereafter until study completion, with a minimum follow-up of 3 years for each participant. | Cardiac autonomic function will be assessed using time-domain and frequency-domain heart rate variability parameters obtained from electrocardiographic monitoring. Measurements will be centrally analyzed by the blinded ECG Core Laboratory. | ClinicalTrials.gov |
| Secondary | Health-Related Quality of Life Assessed Using the EuroQol 5-Dimension 5-Level Questionnaire | At 3 months, 1 year, and annually thereafter until study completion, with a minimum follow-up of 3 years for each participant. | Health-related quality of life will be assessed using the EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L). An EQ-5D-5L health utility index will be calculated using the Chinese population value set. The index ranges from -0.391 to 1.000, with higher scores indicating better health status. A score of 1.000 represents full health, 0 represents a health state equivalent to death, and negative values represent health states considered worse than death. Scores will be compared between the two treatment groups at scheduled follow-up assessments. | ClinicalTrials.gov |
| Secondary | Atrial Fibrillation-Related Quality of Life Assessed Using the Atrial Fibrillation Effect on QualiTy-of-Life Questionnaire | At 3 months, 1 year, and annually thereafter until study completion, with a minimum follow-up of 3 years for each participant. | Atrial fibrillation-related quality of life will be assessed using the Atrial Fibrillation Effect on QualiTy-of-Life Questionnaire (AFEQT). The AFEQT Overall Summary Score ranges from 0 to 100, with higher scores indicating better atrial fibrillation-related health status and quality of life and lower scores indicating greater impairment. Scores will be compared between the two treatment groups at scheduled follow-up assessments. | ClinicalTrials.gov |
| Secondary | Incidence of Reoperation for Bleeding | From the date of surgery through discharge from the index hospitalization (an estimated period of up to 30 days). | The proportion of participants who require surgical re-exploration because of postoperative bleeding. | ClinicalTrials.gov |
| Secondary | Incidence of Postoperative Blood Transfusion | From the date of surgery through discharge from the index hospitalization (an estimated period of up to 30 days). | The proportion of participants who receive a blood transfusion after surgery during the index hospitalization. | ClinicalTrials.gov |
| Secondary | Incidence of Delayed Moderate or Greater Pericardial Effusion | From discharge from the index hospitalization through 30 days after discharge. | The proportion of participants who develop new-onset moderate or greater pericardial effusion within 30 days after discharge from the index hospitalization, as documented by echocardiography. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)